Glasgow Asthma and Allergy Study
GLAAS
Cross Sectional Study to Evaluate and Associate Clinical and Laboratory Features of People With Allergic and Non-allergic Asthma
1 other identifier
observational
105
1 country
1
Brief Summary
In the past, doctors separated people with asthma into two groups, those with "allergic asthma" (about 2/3rds of people) and those with "non-allergic asthma". These labels are not much used now as the treatments for all people with asthma don't depend on this classification. However, new treatments for asthma may become available and the classification may again become important. It could be useful for clinicians to know how to identify which patients are likely to benefit from particular treatments. Additionally, some new blood tests are becoming available and some of these might help to categorise the type of asthma people have. What the study hopes to do is to identify patient features which make a diagnosis of "allergic asthma" more likely and to see which new blood tests are most likely to be helpful in confirming this diagnosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2012
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2012
CompletedFirst Submitted
Initial submission to the registry
June 8, 2012
CompletedFirst Posted
Study publicly available on registry
June 13, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2013
CompletedDecember 5, 2013
December 1, 2013
1.3 years
June 8, 2012
December 4, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum periostin level
This is a cross sectional study. Participants will be assessed and tests conducted at a single visit
1 day
Secondary Outcomes (7)
skin prick test
1 day
Serum total IgE
1 day
Blood eosinophil count
1 day
Blood neutrophil count
1 day
Blood CD4 cells that are positive for CRTh2
1 day
- +2 more secondary outcomes
Study Arms (1)
General asthma population
People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria.
Eligibility Criteria
People with asthma, non smoker, aged 18 and over.
You may qualify if:
- Male and female patients aged 18 years old and over with a diagnosis of asthma and having received at least two prescriptions for any asthma medication in the last 12 months, who have signed an informed consent form prior to initiation of any study-related procedure
You may not qualify if:
- under 18 years
- current smokers
- unwilling or unable to give informed consent
- a clinical diagnosis of COPD
- a history of anaphylaxis (skin prick test)
- participated in any clinical study in the last 12 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
NSHI Ltd
Dartford, Kent, DA1 5GA, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
John A Haughney, MB ChB
NSHI Ltd
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 8, 2012
First Posted
June 13, 2012
Study Start
June 1, 2012
Primary Completion
October 1, 2013
Study Completion
October 1, 2013
Last Updated
December 5, 2013
Record last verified: 2013-12